The initial success of Sildenafil undeniably reshaped the pharmaceutical landscape, but placing funds in companies primarily reliant on off-patent versions presents a challenging picture. Despite early profits were substantial, the end of patents and the rise of cheaper alternatives have weakened the customer base. Therefore, a thorough evaluation